An open-label, first-in-human, dose escalation study of a novel CD3-CD123 bispecific T-cell engager administered as a single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or high risk myelodysplastic syndrome.

被引：4

作者：

Boissel, Nicolas

de Botton, Stephane

Thomas, Xavier G.

Rao, Ercole

Bonnevaux, Helene

Rubin-Carrez, Chantal

Guerif, Stephane

Beys, Eric

Gosselin, Alice

Bauchet, Anne-Laure

Novikov, Valery

Fernandes, Elma

Wiederschain, Dmitri

Palatinsky, Emanuel A.

Hsu, Karl

Fraenkel, Paula Goodman

机构：

[1] Hop St Louis, Paris, France

[2] Inst Gustave Roussy, INSERM, U1170, Villejuif, France

[3] Ctr Hosp Lyon Sud, Lyon, France

[4] Sanofi, Frankfurt, Germany

[5] Sanofi, Vitry Sur Seine, France

[6] Sanofi, Alfortville, France

[7] Sanofi, Bridgewater, NJ USA

[8] Sanofi, Cambridge, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期

关键词：

D O I：

10.1200/JCO.2018.36.15_suppl.TPS7076

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7076

引用

页数：1

共 50 条

[31] Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Watts, Justin M.
Lin, Tara
Wang, Eunice S.
Mims, Alice S.
Cull, Elizabeth H.
Patel, Prapti A.
Shami, Paul J.
Walter, Roland B.
Cogle, Christopher R.
Chenault, Ruth A.
Macpherson, Bret
Chunyk, Allison Given
McMahan, Catherine J.
Gross, Jane A.
Stromatt, Scott
BLOOD, 2020, 136
[32] Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia
Wang, Ying
Yin, Qingsong
Ren, Jinhai
Zhou, Hongsheng
Gong, Tiejun
Zhu, Feng
Zhang, Xi
Wen, Qin
Mei, Heng
Huang, Wei
Li, Haiying
Wang, Jianxiang
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[33] Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
Yang, Junfang
He, Jiaping
Zhang, Xian
Li, Jingjing
Wang, Zhenguang
Zhang, Yongliang
Qiu, Liyuan
Wu, Qionglu
Sun, Zhe
Ye, Xun
Yin, Wenjie
Cao, Wei
Shen, Lianjun
Sersch, Martina
Lu, Peihua
BLOOD CANCER JOURNAL, 2022, 12 (07)
[34] Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study
Junfang Yang
Jiaping He
Xian Zhang
Jingjing Li
Zhenguang Wang
Yongliang Zhang
Liyuan Qiu
Qionglu Wu
Zhe Sun
Xun Ye
Wenjie Yin
Wei Cao
Lianjun Shen
Martina Sersch
Peihua Lu
Blood Cancer Journal, 12
[35] Phase II Trial of the Anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
Topp, Max S.
Gokbuget, Nicola
Zugmaier, Gerhard
Klappers, Petra
Stelljes, Matthias
Neumann, Svenja
Viardot, Andreas
Marks, Reinhard
Diedrich, Helmut
Faul, Christoph
Reichle, Albrecht
Horst, Heinz-August
Brueggemann, Monika
Wessiepe, Dorothea
Holland, Chris
Alekar, Shilpa
Mergen, Noemi
Einsele, Hermann
Hoelzer, Dieter
Bargou, Ralf C.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (36) : 4134 - U363
[36] Preliminary pharmacokinetics (PK) and pharmacodynamic (PD) analysis of the CD123 NK cell engager (NKCE) SAR443579 in patients (pts) with relapsed or refractory acute myeloid leukemia (R/R AML), B cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
Jongen-Lavrencic, M.
Bajel, A.
Garciaz, S.
Maiti, A.
Fleming, S.
De Button, S.
Huls, G. A.
Jensen, K.
Ziti-Ljajic, S.
Draganov, D.
Rotolo, F.
Palu, C.
Courta, J.
Passe-Coutrin, W.
Traudtner, K.
Wagenaar, T.
Abbadessa, G.
Stein, A. Selwyn
ANNALS OF ONCOLOGY, 2023, 34 : S543 - S544
[37] First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma
Jongen-Lavrencic, Mojca
Yuda, Junichiro
Mous, Rogier
Olszewski, Adam
Nijland, Marcel
Abedin, Sameem
Calvo, Emiliano
Nuthalapati, Silpa
Motwani, Monica
Modi, Dimple
Mu, Yunming
Petrich, Adam M.
Penugonda, Sudhir
Morillo, Daniel
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S177 - S177
[38] Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Zhang, Xian
Lu, Xin-an
Yang, Junfang
Zhang, Gailing
Li, Jingjing
Song, Lisong
Su, Yunchao
Shi, Yanze
Zhang, Min
He, Jiujiang
Song, Dan
Lv, Fanyong
Li, Wenqian
Wu, Yan
Wang, Hui
Liu, Hongxing
Zhou, Xiaosu
He, Ting
Lu, Peihua
BLOOD ADVANCES, 2020, 4 (10) : 2325 - 2338
[39] Feasibility, and Efficacy of Donor-Derived cd19-Targeted Car t-Cell Therapy in Refractory/Relapsed(r/r)b-Cell Acute Lymphoblastic Leukemia (ball) Patients
Zhang, Xian
Yang, Junfang
Li, Wenqian
Zhang, Gailing
Su, Yunchao
Shi, Yanze
Song, Dan
Zhang, Min
He, Jiujiang
Xu, Li
Qiu, Liyuan
Lu, Xin-An
Wu, Fei
Li, Jianqiang
Chen, Dandan
Li, Xiangqun
Li, Ziyu
Li, Jingjing
Lu, Peihua
BLOOD, 2020, 136
[40] CD22-Directed CAR T-Cell Therapy Mediates Durable Complete Responses in Adults with Relapsed or Refractory Large B-Cell Lymphoma after Failure of CD19-Directed CAR T-Cell Therapy and High Response Rates in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Baird, John H.
Frank, Matthew J.
Craig, Juliana
Patel, Shabnum
Spiegel, Jay Y.
Sahaf, Bita
Younes, Sheren F.
Oak, Jean S.
Natkunam, Yasodha
Ehlinger, Zachary
Reynolds, Warren D.
Arai, Sally
Johnston, Laura J.
Lowsky, Robert
Negrin, Robert S.
Rezvani, Andrew R.
Shiraz, Parveen
Sidana, Surbhi
Weng, Wen-Kai
Schultz, Liora M.
Ramakrishna, Sneha
Davis, Kara L.
Feldman, Steven A.
Mackall, Crystal L.
Miklos, David B.
Muffly, Lori S.
BLOOD, 2020, 136

← 1 2 3 4 5 →